These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 32820647)

  • 1. Recruitment, retention, and adherence in a clinical trial: The Pediatric Heart Network's Marfan Trial experience.
    Hamstra MS; Pemberton VL; Dagincourt N; Hollenbeck-Pringle D; Trachtenberg FL; Cnota JF; Atz AM; Cappella E; De Nobele S; Grima J; King M; Korsin R; Lambert LM; MacNeal MK; Markham LW; MacCarrick G; Sylvester DM; Walter P; Xu M; Lacro RV;
    Clin Trials; 2020 Dec; 17(6):684-695. PubMed ID: 32820647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy.
    Lacro RV; Guey LT; Dietz HC; Pearson GD; Yetman AT; Gelb BD; Loeys BL; Benson DW; Bradley TJ; De Backer J; Forbus GA; Klein GL; Lai WW; Levine JC; Lewin MB; Markham LW; Paridon SM; Pierpont ME; Radojewski E; Selamet Tierney ES; Sharkey AM; Wechsler SB; Mahony L;
    Am Heart J; 2013 May; 165(5):828-835.e3. PubMed ID: 23622922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atenolol versus losartan in children and young adults with Marfan's syndrome.
    Lacro RV; Dietz HC; Sleeper LA; Yetman AT; Bradley TJ; Colan SD; Pearson GD; Selamet Tierney ES; Levine JC; Atz AM; Benson DW; Braverman AC; Chen S; De Backer J; Gelb BD; Grossfeld PD; Klein GL; Lai WW; Liou A; Loeys BL; Markham LW; Olson AK; Paridon SM; Pemberton VL; Pierpont ME; Pyeritz RE; Radojewski E; Roman MJ; Sharkey AM; Stylianou MP; Wechsler SB; Young LT; Mahony L;
    N Engl J Med; 2014 Nov; 371(22):2061-71. PubMed ID: 25405392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Rapid Aortic Root Dilation and Referral for Aortic Surgery in Marfan Syndrome.
    Hoskoppal A; Menon S; Trachtenberg F; Burns KM; De Backer J; Gelb BD; Gleason M; James J; Lai WW; Liou A; Mahony L; Olson AK; Pyeritz RE; Sharkey AM; Stylianou M; Wechsler SB; Young L; Levine JC; Tierney ESS; Lacro RV; Bradley TJ;
    Pediatr Cardiol; 2018 Oct; 39(7):1453-1461. PubMed ID: 29948025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome.
    Handisides JC; Hollenbeck-Pringle D; Uzark K; Trachtenberg FL; Pemberton VL; Atz TW; Bradley TJ; Cappella E; De Nobele S; Groh GK; Hamstra MS; Korsin R; Levine JC; Lindauer B; Liou A; Neal MKM; Markham LW; Morrison T; Mussatto KA; Olson AK; Pierpont MEM; Pyeritz RE; Radojewski EA; Roman MJ; Xu M; Lacro RV;
    J Pediatr; 2019 Jan; 204():250-255.e1. PubMed ID: 30270167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.
    Van Driest SL; Sleeper LA; Gelb BD; Morris SA; Dietz HC; Forbus GA; Goldmuntz E; Hoskoppal A; James J; Lee TM; Levine JC; Li JS; Loeys BL; Markham LW; Meester JAN; Mital S; Mosley JD; Olson AK; Renard M; Shaffer CM; Sharkey A; Young L; Lacro RV; Roden DM
    J Pediatr; 2020 Jul; 222():213-220.e5. PubMed ID: 32586526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome.
    Selamet Tierney ES; Levine JC; Chen S; Bradley TJ; Pearson GD; Colan SD; Sleeper LA; Campbell MJ; Cohen MS; De Backer J; Guey LT; Heydarian H; Lai WW; Lewin MB; Marcus E; Mart CR; Pignatelli RH; Printz BF; Sharkey AM; Shirali GS; Srivastava S; Lacro RV;
    J Am Soc Echocardiogr; 2013 Jun; 26(6):657-66. PubMed ID: 23582510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial and ethnic differences in response to treatment for Marfan syndrome.
    Ayers R; Kelleman M; Iannucci G; McCracken C; Oster ME
    Cardiol Young; 2021 Dec; 31(12):1991-1998. PubMed ID: 33845931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome].
    Forteza A; Evangelista A; Sánchez V; Teixidó G; García D; Sanz P; Gutiérrez L; Centeno J; Rodríguez-Palomares J; Cortina J; García-Dorado D
    Rev Esp Cardiol; 2011 Jun; 64(6):492-8. PubMed ID: 21561700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.
    Teixido-Tura G; Forteza A; Rodríguez-Palomares J; González Mirelis J; Gutiérrez L; Sánchez V; Ibáñez B; García-Dorado D; Evangelista A
    J Am Coll Cardiol; 2018 Oct; 72(14):1613-1618. PubMed ID: 30261963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.
    Lacro RV; Dietz HC; Wruck LM; Bradley TJ; Colan SD; Devereux RB; Klein GL; Li JS; Minich LL; Paridon SM; Pearson GD; Printz BF; Pyeritz RE; Radojewski E; Roman MJ; Saul JP; Stylianou MP; Mahony L;
    Am Heart J; 2007 Oct; 154(4):624-31. PubMed ID: 17892982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric Heart Network Trial of Losartan vs. Atenolol in Children and Young Adults with Marfan Syndrome: Impact on Prescription Practices.
    Robertson DM; Truong DT; Cox DA; Carmichael HL; Ou Z; Minich LL; Williams RV; Selamet Tierney ES
    Pediatr Cardiol; 2023 Mar; 44(3):618-623. PubMed ID: 35902413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial.
    Forteza A; Evangelista A; Sánchez V; Teixidó-Turà G; Sanz P; Gutiérrez L; Gracia T; Centeno J; Rodríguez-Palomares J; Rufilanchas JJ; Cortina J; Ferreira-González I; García-Dorado D
    Eur Heart J; 2016 Mar; 37(12):978-85. PubMed ID: 26518245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
    Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of Ventricular Arrhythmias and Other Rhythm Abnormalities in Children and Young Adults With the Marfan Syndrome.
    Mah DY; Sleeper LA; Crosson JE; Czosek RJ; Love BA; McCrindle BW; Muiño-Mosquera L; Olson AK; Pilcher TA; Tierney ESS; Shah MJ; Wechsler SB; Young LT; Lacro RV
    Am J Cardiol; 2018 Oct; 122(8):1429-1436. PubMed ID: 30115424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.
    Chiu HH; Wu MH; Wang JK; Lu CW; Chiu SN; Chen CA; Lin MT; Hu FC
    Mayo Clin Proc; 2013 Mar; 88(3):271-6. PubMed ID: 23321647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome.
    Selamet Tierney ES; Levine JC; Sleeper LA; Roman MJ; Bradley TJ; Colan SD; Chen S; Campbell MJ; Cohen MS; De Backer J; Heydarian H; Hoskoppal A; Lai WW; Liou A; Marcus E; Nutting A; Olson AK; Parra DA; Pearson GD; Pierpont ME; Printz BF; Pyeritz RE; Ravekes W; Sharkey AM; Srivastava S; Young L; Lacro RV;
    Am J Cardiol; 2018 May; 121(9):1094-1101. PubMed ID: 29631804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using the consolidated framework for implementation research to identify recruitment barriers and targeted strategies for a shared decision-making randomized clinical trial in pediatric sickle cell disease.
    Strong H; Hood AM; Johnson Y; Hackworth R; Reed-Shackelford M; Ramaswamy R; Varughese T; Quinn CT; Crosby LE
    Clin Trials; 2023 Jun; 20(3):211-222. PubMed ID: 36794731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes.
    Sandor GG; Alghamdi MH; Raffin LA; Potts MT; Williams LD; Potts JE; Kiess M; van Breemen C
    Int J Cardiol; 2015 Jan; 179():470-5. PubMed ID: 25465809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome.
    Bhatt AB; Buck JS; Zuflacht JP; Milian J; Kadivar S; Gauvreau K; Singh MN; Creager MA
    Vasc Med; 2015 Aug; 20(4):317-25. PubMed ID: 25795452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.